SCHEMBL16632529

SCHEMBL16632529

C=C(Cl)Cc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 2/20 0.52
CASP1 P29466 1/20 0.52
ALDH1A1 P00352 6/20 0.47
TP53 P04637 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.46
DCLRE1B Q9H816 1/20 0.44
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 2/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.42
MYC P01106 1/20 0.41
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
PTGDR Q13258 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1022607 0.84 SMN1; SMN2 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL16632709 0.81 ABL1 (0.54) SMN1; SMN2ALDH1A1CA1CA2MRGPRX4
SCHEMBL1548854 0.78 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL8482265 0.78 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL8482266 0.78 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL16632745 0.78 XDH (0.41) MRGPRX4
SCHEMBL2541137 0.77 PTGDR (0.59) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL8574539 0.77 SMN1; SMN2 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53
SCHEMBL13870495 0.77 SMN1; SMN2 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53
Ethane SCHEMBL7194508 0.77 SMN1; SMN2 (0.57) SMN1; SMN2TSHRCASP1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR SMN1; SMN2 3595/4885TSHR 4583/4885CASP1 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.